NuVasive

Insiders Take Advantage Of NuVasive Pullback After Earnings

NuVasive Announces Acquisition Of Ellipse Technologies, Notes 'Potential To Become The Standard Of Care'

Market Wrap For January 15: Bulls Take Over As Economic Growth Remains Healthy

NuVasive Announces Acquisition Of Ellipse Technologies, Notes 'Potential To Become The Standard Of Care'

Market Wrap For January 15: Bulls Take Over As Economic Growth Remains Healthy

Starbucks, Huntington Bancshares and Other Stocks Insiders Are Buying

Esterline, Janus Capital and Other Stocks Insiders Are Buying

Starbucks, Huntington Bancshares and Other Stocks Insiders Are Buying

Esterline, Janus Capital and Other Stocks Insiders Are Buying

Medtronic, Snyder's-Lance and Other Stocks Insiders Are Buying

UPDATE: JP Morgan Raises PT on NuVasive from $33 to $34

NuVasive Recent News

Fifteen Health Care ETFs Trading Near 52-Week Highs

BMO Capital Upgrades NuVasive to Outperform from Market Perform

Twelve Health Care ETFs Trading Near 52-Week Highs

Bank of America Provides Color on NuVasive, Buy

Bank of America Merrill Lynch Reiterates Buy on Nuvasive

Jefferies Comments On NuVasive 1Q Results

UPDATE: J.P. Morgan Color On NUVA Target Increase

JP Morgan Raises PT On NuVasive To $33

Piper Jaffray Reiterates Overweight Rating On NuVasive

J.P. Morgan To Adjust Ratings For NuVasive Following 4Q10 Results

NUVA 4Q Upside Encouraging But Visibility Remains Poor, J.P. Morgan Reports

Piper Jaffray Raises PT On NuVasive To $39

Jefferies Remains Positive On NUVA, Lowers PT To $34 From $36

NUVA Amends 2011 Outlook, J.P. Morgan Reports

Jefferies Lowers PT On NuVasive

JP Morgan Upgrades NuVasive To Neutral

J.P. Morgan Lowers Estimates, Downgrades NuVasive Rating

PiperJaffray Lowers NuVasive (NUVA) Price Target, Reiterates Overweight Rating